High-risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse

Br J Haematol. 2021 Oct;195(2):283-286. doi: 10.1111/bjh.17670. Epub 2021 Jul 9.

Authors

Eileen M Boyle¹, Adam Rosenthal², Yan Wang³, Philip Farmer³, Michael Rutherford³, Cody Ashby³, Michael Bauer³, Sarah K Johnson⁴, Christopher P Wardell³, Antje Hoering², Carolina Schinke⁴, Sharmilan Thanendrarajan⁴, Maurizio Zangari⁴, Bart Barlogie⁴, Faith E Davies¹, Brian A Walker⁵, Frits van Rhee³, Gareth J Morgan¹

Affiliations

¹ Perlmutter Cancer Center, NYU Langone Medical Center, Myeloma Research Program, New York, NY, USA.
² Cancer Research and Biostatistics - CRAB, Seattle, USA.
³ Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
⁴ Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
⁵ Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology Oncology, Indiana University, Indianapolis, IN, USA.

PMID: 34244996
DOI: 10.1111/bjh.17670

No abstract available

Keywords: gene expression; myeloma; risk factors.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Cell Proliferation / genetics
Gene Expression Profiling / methods*
Gene Expression Profiling / statistics & numerical data
Humans
Multiple Myeloma / diagnosis
Multiple Myeloma / genetics*
Multiple Myeloma / pathology*
Neoplasm Recurrence, Local / genetics*
Plasma Cells / metabolism
Precision Medicine
Recurrence
Remission Induction
Risk Factors
Syndecan-1 / genetics
Transcriptional Activation / genetics

Substances

Syndecan-1